We are pleased to announce that Gaby Talarico has joined our board, adding another valuable patient voice to guide and inform our work. Now approaching 30 years old, Gaby was diagnosed with APS Type 1 at the age of 11 and was the first participant in the Natural History Study at the National Institutes of…
Read More
As Heather Talarico retires from our board of directors, the APS Type 1 Foundation extends its heartfelt gratitude to Heather for her dedicated service to our community over many years. As a co-founder of the Foundation, Heather has been a driving force behind our success. Her relentless efforts, including a decade of organizing the Driving…
Read More
Diabetes Center Director, UCSF, Mark Anderson MD PhD has been awarded the prestigious Coley Award from the Cancer Research Institute. The Coley Award honors groundbreaking contributions to cancer research, validating and highlighting the impact of innovative work, particularly in immunotherapy and recognizes Dr. Anderson’s foundational contributions to the understanding of immune tolerance mechanisms, self-antigen presentation,…
Read More
We are excited to announce the FDA’s approval of Yorvipath®, as the only FDA approved treatment for hypoparathyroidism in adults. YORVIPATH is a prodrug of parathyroid hormone (PTH[1-34]), administered once daily, designed to provide continuous exposure to released PTH over the 24-hour dosing period. Hypoparathyroidism is a rare endocrine disease caused by insufficient levels of…
Read MoreCongratulations are due to two of our graduating seniors: Sarah Brennan and Brooklyn Dwyer. Navigating the teen years and high school is hard enough without the added challenge of a rare disease. These two young women inspire us all to never give up and reach our dreams. We wish you both the very best in…
Read More
Congratulations to our medical advisory committee members, Drs. Michail Lionakis and Maureen Su, on their recent publications in the prestigious New England Journal of Medicine, entitled The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1 and JAK Inhibition Immunotherapy for APS-1, respectively. In his article, Dr. Lionakis, whose work led to the first-ever clinical trial for APS Type…
Read MoreWe are excited to share that Kayla Mills, one of our young adults with APS Type 1, was crowned Miss Arc Broward on May 19, 2024. The Miss Arc Broward Pageant empowers girls and teens with disabilities to pursue their dreams. Kayla is literally using her voice to advocate for others like her with “hidden”…
Read More
The APS Type 1 Foundation, with generous sponsorship by the Clinical Immunology Society and the National Institute of Allergy and Infectious Disease, hosted a FOCIS (Federation of Clinical Immunology Societies) Member Society Symposium at the FOCIS 2024 Annual Meeting in San Francisco on June 18th. Over 120 clinicians and scientists attended. The speakers delivered incredible talks about cutting-edge research relating to APS…
Read More
The National Adrenal Diseases Foundation (NADF) is a patient advocacy organization whose mission is to advance education, support, and research to improve the lives of those affected by adrenal diseases. Today, we share NADF’s June 2024 newsletter.
Read More
Meet Svetlana Hutfles We are delighted to share a momentous occasion in our journey towards finding a cure for APS Type 1 and supporting those affected by this rare disease. Thanks to the generosity of our dedicated donors and supporters, The APS Type 1 Foundation is proud to announce that it has hired its inaugural…
Read MoreCOPENHAGEN, Denmark, May 14, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food and Drug Administration (FDA) notified the Company that information submitted in response to the FDA’s ongoing review of the New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism constituted a major amendment to the NDA. Accordingly, the FDA has…
Read More